Ajay K. Nooka, MD

A review of the study design and results of two clinical trials researching quadruplet therapies for newly diagnosed multiple myeloma presented at ASH 2021.

An overview of the currently available frontline treatment options for transplant-eligible multiple myeloma.

Ajay K. Nooka, MD, MPH, FACP discussed the clinical benefits of belantamab mafodotin in combination with bortezomib/dexamethasone to treat multiple myeloma.

In this article, we elucidate the rationale for use of novel drug combinations in patients with myeloma, and review current evidence-based data supporting the use of specific combinations in various settings. We also attempt to craft a framework to guide clinicians in optimizing the use of combination therapies, to enable patients to derive maximal benefit.

This article reviews the hematologic safety profile of carfilzomib in patients with relapsed/refractory multiple myeloma, as assessed in a cross-trial safety analysis of four phase II studies, and makes recommendations for the appropriate management of hematologic adverse events.